Condition

Mucinous Breast Cancer Stage II

ClinicalTrials.gov condition label

Clinical trials4

Recruiting0

Common interventions11

Lead sponsors shown1

Clinical trials

4 shown

Denosumab as an add-on Neoadjuvant Treatment (GeparX)NCT02682693 · 2017-02-13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)NCT02125344 · 2014-12-01

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)NCT01583426 · 2012-07-01

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast CancerNCT01426880 · 2011-08-01

Common interventions

CarboplatinDRUG3 CyclophosphamideDRUG2 EpirubicinDRUG2 nab-PaclitaxelDRUG2 PaclitaxelDRUG2 PertuzumabDRUG2 TrastuzumabDRUG2 background treatmentDRUG1 DenosumabDRUG1 Ferric carboxymaltoseDRUG1 non-pegylated liposomal doxorubicinDRUG1

Leading sponsors

GBG Forschungs GmbH4

Trial status mix

COMPLETED4

Phase mix

PHASE33

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.